These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9845091)

  • 1. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
    Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
    Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioreductive therapy.
    Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
    [No Abstract]   [Full Text] [Related]  

  • 5. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductive drugs in cancer therapy.
    Stratford IJ
    BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
    Walton MI; Sugget N; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of dual function nitrofurans in rodent and human tumor cells.
    Siemann DW
    Int J Radiat Oncol Biol Phys; 1992; 22(4):697-700. PubMed ID: 1544840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroimidazoles as anti-tumor agents.
    Liu K; Zhu HL
    Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
    Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioreductive mechanisms.
    Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A; Godden J; Stratford IJ; Adams GE
    Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT; Greenberg MM; Fuchs T; Gates KS
    Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL
    Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioreductive agents: a clinical update.
    Boyer MJ
    Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
    Phillips RM
    Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK; Piao CQ; He ZY; Hall EJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
    McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
    Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting hypoxia with a new generation of indolequinones.
    Jaffar M; Naylor MA; Robertson N; Stratford IJ
    Anticancer Drug Des; 1998 Sep; 13(6):593-609. PubMed ID: 9755720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.